These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10603312)

  • 1. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.
    Berman PW; Huang W; Riddle L; Gray AM; Wrin T; Vennari J; Johnson A; Klaussen M; Prashad H; Köhne C; deWit C; Gregory TJ
    Virology; 1999 Dec; 265(1):1-9. PubMed ID: 10603312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
    Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
    Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
    Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
    J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.
    Berman PW
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S277-89. PubMed ID: 9814956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
    Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV vaccine development: a subtype E-specific strategy.
    Brown AE; McNeil JG
    Southeast Asian J Trop Med Public Health; 1998 Jun; 29(2):377-82. PubMed ID: 9886132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells.
    Xiao X; Kinter A; Broder CC; Dimitrov DS
    Exp Mol Pathol; 2000 Jun; 68(3):133-8. PubMed ID: 10816381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity considerations in HIV-1 vaccine selection.
    Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
    Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
    LaCasse RA; Follis KE; Trahey M; Scarborough JD; Littman DR; Nunberg JH
    Science; 1999 Jan; 283(5400):357-62. PubMed ID: 9888845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
    Garrido C; Roulet V; Chueca N; Poveda E; Aguilera A; Skrabal K; Zahonero N; Carlos S; García F; Faudon JL; Soriano V; de Mendoza C
    J Clin Microbiol; 2008 Mar; 46(3):887-91. PubMed ID: 18199789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient?
    Lathey JL; Brambilla D; Goodenow MM; Nokta M; Rasheed S; Siwak EB; Bremer JW; Huang DD; Yi Y; Reichelderfer PS; Collman RG
    J Leukoc Biol; 2000 Sep; 68(3):324-30. PubMed ID: 10985247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia.
    Menu E; Reynes JM; Müller-Trutwin MC; Guillemot L; Versmisse P; Chiron M; An S; Trouplin V; Charneau P; Fleury H; Barré-Sinoussi F; Sainte Marie FF
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(5):481-7. PubMed ID: 10225231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.